Outcomes of transplantation with related- and unrelated-donor stem cells in children with severe thalassemia

被引:50
作者
Hongeng, Suradej
Pakakasama, Samart
Chuansumrit, Ampaiwan
Sirachainan, Nongnuch
Kitpoka, Pimpan
Udomsubpayakul, Umaporn
Ungkanont, Artit
Jootar, Saengsuree
机构
[1] Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Pediat, Bangkok 10400, Thailand
[2] Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Pathol, Bangkok 10400, Thailand
[3] Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Internal Med, Bangkok 10400, Thailand
[4] Mahidol Univ, Ramathibodi Hosp, Fac Med, Res Ctr, Bangkok 10400, Thailand
[5] Mahidol Univ, Ramathibodi Hosp, Fac Med, Bone Marrow Transplantat Program, Bangkok 10400, Thailand
关键词
stem cell transplantation; severe thalassemia; children; related donors; unrelated donors;
D O I
10.1016/j.bbmt.2006.02.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recently published reports indicate that the outcome of unrelated donor transplantations in patients with leukemia is currently comparable to that of transplantation from identical family donors. We investigated the possibly favorable outcomes of related and unrelated transplantation in children with severe thalassemia. We reviewed transplantation outcome in 49 consecutive children with severe thalassemia who underwent allogeneic stem cell transplantation with related-donor (n = 28) and unrelated-donor (n = 21) stem cells between September 1992 and May 2005 at the Faculty of Medicine, Ramathibodi Hospital, Mahidol University (Bangkok, Thailand). Analysis of engraftment, frequency of procedure-related complications, and thallassemia-free survival showed no advantage from use of related-donor stem cells. The 2-year thalassemia-free survival estimate for recipients of related-donor stem cells was 82% compared with 71% in the unrelated-donor stem cell group (P =.42). The present study provides evidence to support the view that it is quite reasonable to consider unrelated-donor stem cell transplantation an acceptable therapeutic approach in severe thalassemia, at least for patients who are not fully compliant with conventional treatment and do not yet show irreversible severe complications of iron overload. (C) 2006 American Society for Blood and Marrow Transplantation.
引用
收藏
页码:683 / 687
页数:5
相关论文
共 14 条
[1]  
ANASETTI C, 1995, ANNU REV MED, V46, P169
[2]   Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies [J].
Boeckh, M ;
Nichols, WG ;
Papanicolaou, G ;
Rubin, R ;
Wingard, JR ;
Zaia, Y .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2003, 9 (09) :543-558
[3]   Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplants [J].
Gaziev, D ;
Galimberti, M ;
Lucarelli, G ;
Polchi, P ;
Giardini, C ;
Angelucci, E ;
Baronciani, D ;
Sodani, P ;
Erer, B ;
De Biagi, M ;
Andreani, M ;
Agostinelli, F ;
Donati, M ;
Nesci, S ;
Talevi, N .
BONE MARROW TRANSPLANTATION, 2000, 25 (08) :815-821
[4]   Nonmyeloablative stem cell transplantation with a haploidentical donor in a class 3 lucarelli severe thalassemia patient [J].
Hongeng, S ;
Pakakasama, S ;
Chaisiripoomkere, W ;
Ungkanont, A ;
Jootar, S .
BONE MARROW TRANSPLANTATION, 2004, 34 (03) :271-272
[5]   Outcome of transplantation with unrelated donor bone marrow in children with severe thalassaemia [J].
Hongeng, S ;
Pakakasama, S ;
Chaisiripoomkere, W ;
Chuansumrit, A ;
Sirachainan, N ;
Ungkanont, A ;
Jootar, S .
BONE MARROW TRANSPLANTATION, 2004, 33 (04) :377-379
[6]   Full chimerism in nonmyeloablative stem cell transplation in a β-thalassemia major patient (class 3 Lucarelli) [J].
Hongeng, S ;
Chuansumrit, A ;
Hathirat, P ;
Rerkamnuaychoke, B ;
Chaisiripoomkere, W ;
Jootar, S .
BONE MARROW TRANSPLANTATION, 2002, 30 (06) :409-410
[7]   Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia [J].
Hongeng, S ;
Krance, RA ;
Bowman, LC ;
Srivastava, DK ;
Cunningham, JM ;
Horwitz, EM ;
Brenner, MK ;
Heslop, HE .
LANCET, 1997, 350 (9080) :767-771
[8]   Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFα antibody [J].
Kobbe, G ;
Schneider, P ;
Rohr, U ;
Fenk, R ;
Neumann, F ;
Aivado, M ;
Dietze, L ;
Kronenwett, R ;
Hünerlitürkoglu, A ;
Haas, R .
BONE MARROW TRANSPLANTATION, 2001, 28 (01) :47-49
[9]   Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes [J].
La Nasa, G ;
Giardini, C ;
Argiolu, F ;
Locatelli, F ;
Arras, M ;
De Stefano, P ;
Ledda, A ;
Pizzati, A ;
Sanna, MA ;
Vacca, A ;
Lucarelli, G ;
Contu, L .
BLOOD, 2002, 99 (12) :4350-4356
[10]   Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells [J].
Le Blanc, K ;
Rasmusson, I ;
Sundberg, B ;
Götherström, C ;
Hassan, M ;
Uzunel, M ;
Ringdén, O .
LANCET, 2004, 363 (9419) :1439-1441